|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 5
Zeitschriftenartikel
Rule, S.; Jurczak, W.; Jerkeman, M.; Rusconi, C.; Trneny, M.; Offner, F.; Caballero, D.; Joao, C.; Witzens-Harig, M.; Hess, G.; Bence-Bruckler, I.; Cho, S-G; Thieblemont, C.; Zhou, W.; Henninger, T.; Goldberg, J.; Vermeulen, J. und Dreyling, M.
(2018):
Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.
In: Leukemia, Bd. 32, Nr. 8: S. 1799-1803
Güth, J.-F.; Edelhoff, D.; Goldberg, J. und Magne, P.
(2016):
CAD/CAM Polymer vs Direct Composite Resin Core Buildups for Endodontically Treated Molars Without Ferrule.
In: Operative Dentistry, Bd. 41, Nr. 1: S. 53-63
Magne, P.; Goldberg, J.; Edelhoff, D. und Gueth, J-F
(2016):
Composite Resin Core Buildups With and Without Post for the Restoration of Endodontically Treated Molars Without Ferrule.
In: Operative Dentistry, Bd. 41, Nr. 1: S. 64-75
Lenz, G.; Balasubramanian, S.; Goldberg, J.; Rizo, A.; Schaffer, M.; Phelps, C.; Rule, S. und Dreyling, M.
(2016):
Sequence variants in patients with primary and acquired resistance to Ibrutinib in the phase 3 MCL3001 (RAY) trial.
In: Haematologica, Bd. 101: S. 155
Rule, S.; Dreyling, M.; Hess, G.; Auer, R.; Kahl, B.; Cavazos, N.; Liu, B.; Clow, F.; Goldberg, J.; Beaupre, D.; Vermeulen, J.; Wildgust, M. und Wang, M.
(2016):
Overall survival outcomes in patients with mantle-cell lymphoma (MCL) treated with Ibrutinib in a pooled analysis of 370 patients from 3 international open-label studies.
In: Haematologica, Bd. 101: S. 155